Relearning liver cancer: a study of recurrent cases
Part of Cancer, Digestive system clinical trials.
This trial studies patients with liver cancer, including both the common type (hepatocellular carcinoma) and other types. It aims to understand the cancer better by collecting blood samples and medical information.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (either the common type or another type).
- You are not pregnant.
- You have not had an organ transplant.
- If you have a type of liver cancer that is not the usual kind, you must not have any other cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is creating a database of people with liver cancer (including hepatocellular carcinoma and other types). It aims to collect health information and samples over time to better understand the disease and improve future care. If you join, you will be asked to provide blood and leftover tissue from surgery or biopsy, and to follow up with the research team.
This study tracks patients with liver cancer who have had surgery to see how often the cancer comes back. It may help doctors better understand and predict recurrence.
This study collects blood and tumor tissue samples from people with primary liver cancer who are starting their first treatment (systemic therapy or surgery). The samples help researchers learn more about these cancers and how to improve future treatments.
This study uses a 3D-printed model of your liver tumor to help doctors choose treatment that may prevent the cancer from coming back after surgery. The model predicts how your tumor might respond, so you get the most effective therapy.
This trial uses a computer model to predict if your liver cancer might come back aggressively after surgery. If you are at high risk, you may receive additional treatment before surgery to lower that risk.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
Hear when a new Primary Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.